Imu biosciences

Mapping the immune system in unprecedented detail and scale. IMU is at the forefront of accelerating cell therapy drug development processes, imu biosciences.

Skip to main content. Published: Jan 24, IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease.

Imu biosciences

.

Our objective is to spearhead the development of the next generation of advanced diagnostic tools, setting new standards in medical technology and patient care. Oliver is a leading immunologist specialising on innate immune cells and their use in immuno-oncology, imu biosciences research and development to IND. All rights reserved.

.

IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare. Applying AI-driven data analytics to immunology research crystalised further when COVID emerged, and the team leveraged its technology to understand the human immune response to the virus. IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies. The Company was initially seed funded by the European technology investor Kfund and other angel investors. They believe is their role to support the visionary entrepreneurs who will invent the future. Currently, Molten Ventures is a shareholder in a diverse portfolio of companies including Revolut, Trustpilot, Ledger and Thought Machine.

Imu biosciences

IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare. Applying AI-driven data analytics to immunology research crystalised further when COVID emerged, and the team leveraged its technology to understand the human immune response to the virus. IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies. The Company was initially seed funded by the European technology investor Kfund and other angel investors. About Molten Ventures Molten Ventures plc is one of the most active venture capital firms in Europe, developing and investing in disruptive, high growth technology companies.

Tijori screener

Oliver is a leading immunologist specialising on innate immune cells and their use in immuno-oncology, early research and development to IND. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare. Skip to main content. Ends About Molten Ventures Molten Ventures plc is one of the most active venture capital firms in Europe, developing and investing in disruptive, high growth technology companies. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. Leveraging our advanced immune analytics platform, we address critical development challenges such as donor selection, product characterisation, and patient stratification and monitoring. All rights reserved. IMU is at the forefront of accelerating cell therapy drug development processes. She spent three years in the US, gaining international industry and healthcare experience, as Chief of Staff in a commercial stage molecular diagnostics company and as Entrepreneur in Residence at Duke University. Its advanced AI platform — combined with deep immune data profiling — enables unique insights into the immune system, which plays a critical role in virtually every disease. Mapping the immune system in unprecedented detail and scale. IMU is pioneering the use of innovative, systems-level immunological approaches for patient monitoring and the early detection of graft rejection. Applying AI-driven data analytics to immunology research crystalised further when COVID emerged, and the team leveraged its technology to understand the human immune response to the virus. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. Our science the imu platform Learn more.

IMU Biosciences is coupling deep, systems-level immune profiling with a proprietary AI platform to build a uniquely detailed immune atlas spanning the breadth of human health and disease.

Oliver is a leading immunologist specialising on innate immune cells and their use in immuno-oncology, early research and development to IND. Our objective is to spearhead the development of the next generation of advanced diagnostic tools, setting new standards in medical technology and patient care. We are driven by the belief that in the future, no medical decision will be made without truly understanding a patient's immune system, heralding a new era of precision healthcare. Skip to main content. Ends About Molten Ventures Molten Ventures plc is one of the most active venture capital firms in Europe, developing and investing in disruptive, high growth technology companies. Our science the imu platform Learn more. Our goal is to revolutionise precision medicine, improving its effectiveness, reducing failure rates in clinical trials, and making these therapies more viable in the long run. Published: Jan 24, Tim is Executive Partner at Abingworth, a leading international life sciences investment group, and brings more than 30 years of international investor and management experience in the life sciences industry. IMU Biosciences has further validated and fine-tuned its unique approach in partnership with leading pharmaceutical and biotech companies. This potential is already being recognised by pharma and biotech companies as well as leading academic institutions, offering us multiple opportunities to create significant value from strategic collaborations that leverage our unique approach. IMU is extending these advanced methodologies to novel research areas, including the study of psychosis, broadening the horizons of medical research and patient care. We are thrilled to lead this investment round and support IMU in their journey towards groundbreaking discoveries in healthcare. Our focus encompasses the entirety of the patient journey, including early detection, precise patient stratification, and advanced monitoring for responses, toxicity, and potential relapse. IMU is dedicated to advancing the field of immuno-oncology by exploring the system-level immune signatures of cancer.